You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Development of a topical fixed-dose combination drug for peripheral neuropathic pain.

    SBC: WinSanTor, Inc.            Topic: NINDS

    PROJECT SUMMARY An estimated 30 million people in the United States suffer from some form of peripheral neuropathy, a condition that develops as a result of damage to the peripheral nervous system. The top two major causes of peripheral neuropathy in the US are diabetes mellitus (both T1DM and T2DM) and chemotherapeutic agents. Currently, there are no FDA-approved treatments to prevent or reverse ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Inhibitors of T3SS translocon assembly to combat multi-drug resistant P. aeruginosa

    SBC: MICROBIOTIX, INC.            Topic: NIAID

    Abstract Pseudomonas aeruginosa (PA) is the bacterium most frequently isolated from the respiratory tract of ICU pa- tients in the US and is a major cause of pneumonia in intubated patients. Furthermore, infection with PA gener- ally has a poor prognosis, with an estimated 40-69% of PA ventilator-associated pneumonia (VAP) cases re- sulting in mortality, and more than 30% of survivors suffer recur ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Salmonella typhimurium-based Bacteriotherapy for Orphan Benign Tumors: Neurofibromatosis Type II (NF2)

    SBC: Mulberry Biotherapeutics, Inc.            Topic: NINDS

    Neurofibromatosis type 2 (NF2) is a rare genetic disorder that affects about 1 in 25,000 individuals globally. While usually benign, these tumors result in severe morbidity and mortality in affected individuals. Almost all NF2 patients lose their hearing, and many lose the ability to walk and even to see. NF2 patients’ average age at death is 36 years, many of whom die in adolescence or early ad ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease

    SBC: Planet Biotechnology Incorporated            Topic: NIAID

    Lyme disease (LD) is the most prevalent vector-borne disease in the United States, with up to 300,000 cases a year. LD is caused by several species of the spirochete bacteria Borrelia burgdorferi sensu lato (the Lyme borreliae), which are transmitted by ticks from animal (bird, rodent) reservoirs to human hosts. While a short course of antibiotics is usually effective in eliminating the bacteria a ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Vaccination against Zika virus infection using mosquito NeSt1 protein

    SBC: L2 Diagnostics, LLC            Topic: NIAID

    Arthropod-borne viruses (arboviruses) present a substantial threat to human and animal health worldwide. They are transmitted by hematophagous arthropods, in which mosquitoes are one of the main transmitters. The mosquito specie, Aedes aegypti, is the primary mosquito vector of several widely spread arboviruses as zika, dengue or West Nile viruses. Mosquitoes transmit these pathogens by inoculatin ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Engineering a unique antibody for patients with RA

    SBC: Abwiz Bio, Inc.            Topic: NIAID

    RA is one of the most common chronic autoimmune disorders that can lead to complete joint destruction and severe disability if untreated. There is no cure for RA and up to 50% of RA patients do not respond to anti-TNF therapies as circulating Th-17/IL-17 levels are highly elevated subsequent to TNF blockade. For this subset of RA patients, disruption of a novel pathway that impairs the synergy bet ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. A Portable PET Insert System for Simultaneous TOF-PET and MR Brain Imaging

    SBC: PETcoil, Inc.            Topic: 101

    Project Summary Medical imaging technologies such as magnetic resonance imaging (MRI) and positron emission tomography (PET) have been widely used in studying the underlying mechanisms of mental illnesses and neurological disorders such as brain tumors, Alzheimer’s disease, epilepsy, and depression, etc. However, PET and MRI scans are almost always ordered as separate studies on separate machine ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. HBI-002 to Prevent Anthracycline-Related Cardiotoxicity

    SBC: Hillhurst Biopharmaceuticals, Inc.            Topic: NHLBI

    PROJECT SUMMARY There is an urgent need for the development of approaches to prevent cardiotoxicity in cancer patients being treated with anthracyclines, an important class of drugs in the treatment of cancer (e.g. doxorubicin). Anthracycline treatment-related cardiotoxicity is a major clinical problem that severely impacts patient care and also limits dose and usage. More than a quarter of patien ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Multiplexed Bioassay for Checkpoint Inhibitor Autoimmunity

    SBC: L2 Diagnostics, LLC            Topic: NIAID

    The advent of checkpoint inhibitor (CPI) therapy in human cancer has dramatically changed the landscape of treatment strategies in recent years. Previously, cancers with largely ineffective therapeutics and a poor prognosis, such as melanoma, have experienced significant advances of patients able to extend survival and/or progression free disease. Within the tumor microenvironment, a number of imm ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Reversal of Tau Pathology with MSUT2 siRNA Conjugates

    SBC: DTx Pharma, Inc.            Topic: NIA

    Project Summary Genetic and pathologic evidence in andapos;pureandapos; tauopathies such as Progressive Supranuclear Palsy (PSP), Corticobasilar Degeneration (CBD) and some cases of Fronto-temporal Dementia (FTD) directly implicate tau as causing neuronal cell death, while in Alzheimer’s Disease (AD) tau accumulation correlates with development and progression of cognitive impairment. Because of ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government